Ribupatide
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
Fujian Shengdi Pharmaceutical Co · Phase 3 · Completed · Enrollment 567
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Treatment group A: HRS9531 injection | n/r | n/r | n/r | n/r |
| Treatment group B: HRS9531 injection | n/r | n/r | n/r | n/r |
| Treatment group C: HRS9531 injection | n/r | n/r | n/r | n/r |
| Placebo injection | n/r | n/r | n/r | n/r |
Not shown
- Treatment group A: HRS9531 injection: endpoint not reported
- Treatment group B: HRS9531 injection: endpoint not reported
- Treatment group C: HRS9531 injection: endpoint not reported
- Placebo injection: endpoint not reported